Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Bioekvivalensstudie av GZR18-injeksjon før og etter CMC-endring

9. november 2026 oppdatert av: Gan & Lee Pharmaceuticals.

En randomisert, åpen, enkeltdose, parallellsammenligningsstudie for å evaluere bioekvivalensen av GZR18-injeksjon før og etter CMC-endring hos friske voksne mannlige forsøkspersoner

This is an open-label, randomized, single-dose, parallel comparison bioequivalence study conducted in healthy adult male subjects.

The study is divided into 3 parts, each of which evaluates the bioequivalence of GZR18 Injection for one strength before and after CMC changes.

Subjects eligible for each part of the screening will be randomized into Group A or Group B in a 1:1 ratio. Each subject will receive a single dose of GZR18 Injection, followed by PK blood sampling and safety follow-up for 35 days. Subjects will be admitted to the hospital 1 day predose, follow a standardized light diet that evening, and then fast for at least 10 h thereafter. On the day of administration, GZR18 Injection of a single strength will be administered subcutaneously under fasting conditions at a site approximately two finger-widths (2.5 cm) away from the umbilicus on the abdomen. Lunch and dinner will be served approximately 3 and 9 h postdose, respectively.

Venous blood will be collected at 14 time points for GZR18 plasma concentration analysis: at 0 h (within 60 min predose) and 1, 6, 24, 48, 72, 96, 120, 168, 240, 336, 504, 672, and 840 h postdose.

Subjects will undergo corresponding laboratory safety tests at screening, D36, and early withdrawal visits.

During the entire study period, subjects should maintain a light diet, avoid strenuous exercise, and refrain from consuming juice, caffeinated beverages (such as tea and coffee), and alcoholic drinks. Smoking and any other activities that may affect PK observation or safety evaluations are strictly prohibited.

Studieoversikt

Status

Fullført

Forhold

Studietype

Intervensjonell

Registrering (Faktiske)

266

Fase

  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Suzhou
      • Suzhou, Suzhou, Kina
        • The Second Affiliated Hospital of Soochow University

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 50 år (Voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Mann

Beskrivelse

Inclusion Criteria:

  1. Subjects who voluntarily sign the Informed Consent Form (ICF), can receive SC injection, fully understand the content, process and possible adverse reactions of the trial, and are able to follow the regulations on contraindications and restrictions specified in this protocol.

  2. Male, 18 to 50 years of age at signing the ICF (both inclusive).

  3. Weight ≥ 50 kg and body mass index (BMI) within 19-26 kg/m2 (inclusive) at screening.

  4. Subjects of childbearing potential with no birth plan from the signing of ICF to 8 weeks after the last dose, willingness to take effective contraceptive measures, and no plan for sperm donation.

    -

Exclusion Criteria:

  1. Subjects with clinically significant abnormalities detected during the screening period in physical examination, vital signs, laboratory tests, 12-lead ECG, abdominal ultrasound, or chest X-ray, as determined by the investigator.

  2. Subjects who test positive for hepatitis B virus surface antigen, hepatitis C virus IgG antibody, human immunodeficiency virus antibody, P24 antigen, or anti-treponema pallidum antibody.

  3. Subjects with a history of or existing circulatory, urinary, digestive, respiratory, nervous, endocrine, or psychiatric disorders that, in the investigator's judgment, remain clinically significant.

  4. History of acute or chronic pancreatitis and pancreatic injury before screening.

  5. History or family history of previous or existing medullary thyroid carcinoma, multiple endocrine neoplasia type 2.

  6. Subjects who have used any drugs that alter the activity of drug metabolizing enzymes or transporters within 4 weeks prior to screening, or subjects with acute diseases or concomitant medication from the screening period to before randomization.

  7. Subjects with severe infection or unexplained infection within 4 weeks before screening.

  8. Major surgery within 6 months prior to screening, or scheduled surgery or hospitalization during the study.

  9. Subjects known or suspected to have hypersensitivity to any ingredient of the investigational medicinal product (IMP) (glucagon like peptide-1 receptor agonist (GLP-1RA) or its excipients).

  10. Use of any prescription drugs, over-the-counter drugs or Chinese herbal medicine within 2 weeks prior to screening; use of any GLP-1R agonists or drugs with the same mechanism of action to GLP-1R agonists (such as GLP-1R/glucagon receptor [GCGR] agonists or gastric inhibitory polypeptide receptor [GIPR]/GLP-1R agonists or GIPR/GLP-1R/GCGR agonists) within 3 months prior to screening.

  11. Subjects who have been vaccinated within 1 month before screening or are scheduled for vaccination during the study.

  12. Blood donation or blood loss greater than or equal to 400 mL within 3 months before screening, or blood donation scheduled during the study or within 8 weeks after the end of the study.

  13. History of drug abuse prior to screening; or positive results for drug abuse at screening (D-1).

  14. History of alcohol abuse within 3 months prior to screening, defined as an average intake of more than 14 units per week (1 standard unit=360 mL of beer or 150 mL of 12% wine or 45 mL of 40% spirits); or use of any alcohol-containing products 48 hours before administration; or abnormal results for breath alcohol test at screening (D-1).

  15. Subjects who smoked more than 5 cigarettes per day on average within the 3 months before screening, or who do not agree to abstain from smoking for the duration of the study.

  16. Subjects who engage in strenuous exercise within 48 h before administration of the IMP, or have other factors that may affect drug absorption, distribution, metabolism, or excretion.

  17. Subjects who consume grapefruit or grapefruit-containing products, or any caffeinated or xanthine-containing foods or beverages (such as coffee, tea, cola, or chocolate) within 48 hours before administration of the IMP.

  18. Subjects who have special dietary requirements and cannot adhere to a standardized diet, or who are lactose intolerant.

  19. Subjects with a history of needle phobia and blood phobia, difficulty in blood collection or intolerance to venous blood collection.

  20. Subjects who are investigators or employees of the study site, or family members of the employees or investigators.

  21. Participation in a clinical study of another IMP or device within 3 months before screening, or within 5 half-lives of the previous IMP (whichever is longer). Or plan to participate in another clinical study of an IMP or device before completing all scheduled assessments in the clinical study.

    -

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Annen
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: GZR18-injeksjon A2

Administered SC

Eksperimentell: GZR18-injeksjon B2

Single dose, s.c.

Eksperimentell: GZR18-injeksjon A3

Administered SC

Eksperimentell: GZR18-injeksjon B3

Single dose, s.c.

Eksperimentell: GZR18 injection A1

Single dose, s.c.

Administered SC

Eksperimentell: GZR18 injection B1

Single dose, s.c.

Single dose, s.c.

Hva måler studien?

Primære resultatmål

Resultatmål
Tidsramme
den maksimale konsentrasjonen (Cmax)
Tidsramme: Dag1-Dag36
Dag1-Dag36
arealet under konsentrasjon-tid-kurven i løpet av en doseringsintervall (AUC0-t)
Tidsramme: Dag1-Dag36
Dag1-Dag36
arealet under konsentrasjon-tid-kurven fra doseringstidspunktet ekstrapolert til uendelig (AUC0-∞)
Tidsramme: Dag1-Dag36
Dag1-Dag36

Sekundære resultatmål

Resultatmål
Tidsramme
AUC ekstrapolert fra siste tidspunkt ekstrapolert til uendelig i prosent av AUC0-∞ (AUC_%Ekstra)
Tidsramme: Dag1-Dag36
Dag1-Dag36
tidspunkt for maksimal observert konsentrasjon (Tmax)
Tidsramme: Dag1-Dag36
Dag1-Dag36
eliminasjonshalveringstid (t1/2)
Tidsramme: Dag1-Dag36
Dag1-Dag36
eliminasjonshastighetskonstant for plasmakonsentrasjon i terminalfasen (λz)
Tidsramme: Dag1-Dag36
Dag1-Dag36
Behandlingsrelaterte bivirkninger (TEAEs)
Tidsramme: Dag1-Dag36
Dag1-Dag36

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

9. januar 2026

Primær fullføring (Faktiske)

22. mai 2026

Studiet fullført (Faktiske)

22. mai 2026

Datoer for studieregistrering

Først innsendt

5. januar 2026

Først innsendt som oppfylte QC-kriteriene

13. januar 2026

Først lagt ut (Faktiske)

21. januar 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

10. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

9. november 2026

Sist bekreftet

1. januar 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • GZR18-OOO-108

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere